AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaStocks · News reference
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.3% on an annualized basis producing an average annual return of 13.64%. Currently, Amgen has a market capitalization of $197.77 billion.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 9:00 PM
- Checked
- Jul 21, 2026, 9:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzingaAmgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-inc